

OCTOBER 2019

PRESS RELEASE

LIVERHOPE SAFETY STUDY

The **Liverhope Safety study** has been made available online in **The Lancet Gastroenterology and Hepatology** the **14th of October 2019**, together with a comment on the impact of this study.

The study is the result of **3 years** work of the **Liverhope Consortium**, developing the first clinical trial of the **Liverhope Project** a European H2020 backed project. The direct results from the trial show that the safe dose of simvastatin to use in combination with rifaximin for patients with decompensated cirrhosis is **Simvastatin 20 mg**.

This study has laid the groundwork for selecting a **safe dose of simvastatin** for the **Liverhope Efficacy Trial**, that is **currently ongoing** and will hopefully elucidate if the combination of these two drugs is useful as a treatment for the prevention of the progression of cirrhosis and development of **Acute-On-Chronic Liver Failure**.

